


REMARKS

Reconsideration and allowance of the above-referenced application are respectfully requested.


Applicants' attorney apologizes for the inadvertent errors with respect to the inconsistency between 1) the clean version of claim 10 and the marked up version of claim 10 and 2) the clean version of claim 14 (listed as claim 13) and the marked up version of claim 14, appearing in the Amendment and Response of January 15, 2003. It is believed that such errors have been remedied herein.



23492

ABBOTT LABORATORIES
Telephone: (847) 935-1729
Facsimile: (847) 938-2623

Respectfully submitted,
D. Shah, et al.


Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants

MARKED UP VERSION SHOWING CHANGES MADE

Please amend the subject application as follows:

IN THE CLAIMS:

Please amend claims 10 and 14 as follows:

10. (amended) The method of claim 9 wherein said at least one antibody coated on said solid phase is a monoclonal antibody selected from the group consisting of [13-959-270, 14-1269-281, 14-1287-25, 14-153-234, 14-153-462, 14-1705-225, 14-1708-269, 14-1708-403, 14-178-125, 14-188-104, 14-283-112, 14-635-225, 14-726-217, 14-886-216, 14-947-104, 14-945-218, 13-975-157 and 14-1350-210,] 107-35-54, 110-81-17, 13-975-157, 14-1350-210, C11-3, C11-7, C11-10[,] and C11-14 [and C11-15].

14. (amended) The kit of claim 12 or claim 13 further comprising at least one conjugate comprising a signal-generating compound attached to an antibody.